Erythema multiforme associated with candesartan cilexetil

Southern Medical Journal

Volumn 97, Issue 6, 2004, Pages 614-615

  Ejaz, A Ahsan ^a,b   Walsh, John S ^a   Wasiluk, Andrew ^a  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

Candesartan cilexetil; Erythema multiforme

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; ESOMEPRAZOLE; LABETALOL; ROFECOXIB;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; HUMAN; HYPERTENSION; LIP BIOPSY; LIP DISEASE; MALE; UPPER LIP;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; ERYTHEMA MULTIFORME; HUMANS; HYPERTENSION; LIP DISEASES; MALE; MIDDLE AGED; PENILE DISEASES; TETRAZOLES;

EID: 3042658386     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200406000-00023     Document Type: Article

References (6)

1. Trenkwalder P. Efficacy and tolerability of candesartan cilexetil in special patient groups. Blood Press Suppl 2000;1:27-30.
2. Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002;41:7-17.
3. Leaute-Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000;83:347-352.
4. Kaplan AP. Drug-induced skin disease. J Allergy Clin Immunol 1984;74:573-579.
5. Delafuente JC. Drug-induced erythema multiforme: a possible immunologic pathogenesis. Drug Intell Clin Pharm 1985;19:114-117.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.